Lung Cancer
Conference Coverage
Nivolumab shows promise in early-stage resectable NSCLC
The majority of 20 patients with resectable NSCLC were alive and recurrence-free 1 year after surgery and nivolumab treatment.
Original Report
Analgesic management in radiation oncology for painful bone metastases
From the Journals
Bisphosphonate use linked with lower risk of lung cancer for never-smokers
Use of oral bisphosphonates was associated with a lower risk of developing lung cancer in postmenopausal women, but only those who were never...
Conference Coverage
Checkpoint inhibition less toxic than antiangiogenic therapy in NSCLC
ORLANDO – Checkpoint blockade associated with less combined direct and indirect toxicity, a systematic review and meta-analysis suggests.
From the Journals
Nivolumab helps some with advanced NSCLC reach 5-year mark
For 129 patients with previously treated advanced non-small cell lung cancer, the estimated 5-year overall survival rate was 16%.
Conference Coverage
CBC data can predict immunotherapy responses in NSCLC
ORLANDO – Readily available complete blood count data can help predict response to immunotherapy in patients with advanced NSCLC.
From the Journals
Lower socioeconomic status linked with poor NSCLC prognosis in those with pretreatment weight loss
Socioeconomic status, as measured by insurance status, was significantly prognostic among patients with NSCLC and pretreatment weight loss, but...
News
FDA wants data on role of flavored tobacco products in youth initiation
“Youth consistently report product flavoring as a leading reason for using tobacco products,” FDA Commissioner Gottlieb noted.
From the Journals
Fruquintinib promising agent for advanced NSCLC
Median PFS was 3.8 months with fruquintinib versus 1.1 months with placebo in heavily pretreated patients with advanced NSCLC.
From the Journals
Radiation offers no survival benefit in early lung cancer with positive margins
Positive margins were associated with significantly worse 5-year survival in a retrospective study of patients with stage I-II NSCLC, but no...